Wang Bao-Hua, Ou-Yang Jing-Ping
Department of Pathophysiology, School of Medicine, Wuhan University, Dong-Hu Road #115, Wuhan 430071, P. R. China.
Cardiovasc Drug Rev. 2005 Summer;23(2):161-72. doi: 10.1111/j.1527-3466.2005.tb00163.x.
Sodium ferulate (SF) or 3-methoxy-4-hydroxy-cinamate sodium is an active principle from Angelica sinensis, Cimicifuga heracleifolia, Lignsticum chuangxiong, and other plants. It has been used in traditional Chinese medicine and is approved by State Drugs Administration of China as a drug for treatment of cardiovascular and cerebrovascular diseases. SF has antithrombotic, platelet aggregation inhibitory and antioxidant activities in animals and humans. For several decades SF has been widely used in China to treat cardiovascular and cerebrovascular diseases and to prevent thrombosis. Exciting clinical results have been obtained with SF in coronary heart disease, atherosclerosis, pulmonary heart disease and thrombosis. Its safety and efficacy have been demonstrated in clinical practice. This article briefly reviews basic pharmacology, pharmacokinetics, toxicology and clinical pharmacology of SF. The in vitro and in vivo data support the view that SF is a useful drug for the treatment of cardiovascular diseases.
阿魏酸钠（SF）或3-甲氧基-4-羟基肉桂酸钠是当归、升麻、川芎等植物中的一种活性成分。它已被用于传统中药，并被中国国家药品监督管理局批准为治疗心脑血管疾病的药物。SF在动物和人类中具有抗血栓形成、抑制血小板聚集和抗氧化活性。几十年来，SF在中国被广泛用于治疗心脑血管疾病和预防血栓形成。SF在冠心病、动脉粥样硬化、肺心病和血栓形成方面取得了令人兴奋的临床结果。其安全性和有效性已在临床实践中得到证实。本文简要综述了SF的基础药理学、药代动力学、毒理学和临床药理学。体外和体内数据支持SF是一种治疗心血管疾病的有用药物的观点。
